McKay Ryan, Hauk Pricila, Wu Hsuan-Chen, Pottash Alex Eli, Shang Wu, Terrell Jessica, Payne Gregory F, Bentley William E
Fischell Department of Bioengineering, University of Maryland, College Park, Maryland.
Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Maryland.
Biotechnol Bioeng. 2017 Dec;114(12):2883-2895. doi: 10.1002/bit.26391. Epub 2017 Aug 29.
Probiotics, whether taken as capsules or consumed in foods, have been regarded as safe for human use by regulatory agencies. Being living cells, they serve as "tunable" factories for the synthesis of a vast array of beneficial molecules. The idea of reprogramming probiotics to act as controllable factories, producing potential therapeutic molecules under user-specified conditions, represents a new and powerful concept in drug synthesis and delivery. Probiotics that serve as drug delivery vehicles pose several challenges, one being targeting (as seen with nanoparticle approaches). Here, we employ synthetic biology to control swimming directionality in a process referred to as "pseudotaxis." Escherichia coli, absent the motility regulator cheZ, swim sporadically, missing the traditional "run" in the run:tumble swimming paradigm. Upon introduction of cheZ in trans and its signal-generated upregulation, engineered bacteria can be "programmed" to swim toward the source of the chemical cue. Here, engineered cells that encounter sufficient levels of the small signal molecule pyocyanin, produce an engineered CheZ and swim with programmed directionality. By incorporating a degradation tag at the C-terminus of CheZ, the cells stop running when they exit spaces containing pyocyanin. That is, the engineered CheZ modified with a C-terminal extension derived from the putative DNA-binding transcriptional regulator YbaQ (RREERAAKKVA) is consumed by the ClpXP protease machine at a rate sufficient to "brake" the cells when pyocyanin levels are too low. Through this process, we demonstrate that over time, these engineered E. coli accumulate in pyocyanin-rich locales. We suggest that such approaches may find utility in engineering probiotics so that their beneficial functions can be focused in areas of principal benefit.
益生菌,无论是以胶囊形式服用还是在食物中摄取,监管机构都认为其对人类使用是安全的。作为活细胞,它们可充当合成大量有益分子的“可调节”工厂。将益生菌重新编程,使其成为可控工厂,在用户指定条件下生产潜在治疗分子,这一理念在药物合成与递送方面代表了一个全新且强大的概念。作为药物递送载体的益生菌带来了诸多挑战,其中之一就是靶向性(纳米颗粒方法也存在此问题)。在此,我们运用合成生物学来控制一个被称为“假趋化”过程中的游动方向性。缺乏运动调节因子cheZ的大肠杆菌会偶尔游动,在传统的“游动-翻滚”游动模式中缺少“游动”阶段。当通过转导引入cheZ并使其信号诱导上调后,经过工程改造的细菌能够被“编程”,朝着化学信号源游动。在此,遇到足够水平的小信号分子绿脓菌素的工程细胞会产生工程化的CheZ,并以编程的方向性游动。通过在CheZ的C末端加入一个降解标签,当细胞离开含有绿脓菌素的区域时就会停止游动。也就是说,用源自假定的DNA结合转录调节因子YbaQ(RREERAAKKVA)的C末端延伸进行修饰的工程化CheZ,会被ClpXP蛋白酶机器以足够的速率消耗,从而在绿脓菌素水平过低时“制动”细胞。通过这个过程,我们证明随着时间推移,这些经过工程改造的大肠杆菌会在富含绿脓菌素的区域聚集。我们认为,此类方法可能在工程益生菌方面具有实用价值,从而使它们的有益功能能够集中在主要受益区域。